Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Alison Betts, Anne Keunecke, Tamara J. van Steeg, Piet H. van der Graaf, Lindsay B. Avery, Hannah Jones & Jan Berkhout. (2018) Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach. mAbs 10:5, pages 751-764.
Read now
Read now
Yunda Huang, Lily Zhang, Julie Ledgerwood, Nicole Grunenberg, Robert Bailer, Abby Isaacs, Kelly Seaton, Kenneth H. Mayer, Edmund Capparelli, Larry Corey & Peter B. Gilbert. (2017) Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults. mAbs 9:5, pages 792-800.
Read now
Read now
Divya Samineni, Sandhya Girish & Chunze Li. (2016) Impact of Shed/Soluble targets on the PK/PD of approved therapeutic monoclonal antibodies. Expert Review of Clinical Pharmacology 9:12, pages 1557-1569.
Read now
Read now
Articles from other publishers (30)
Anna Dari, Laura Solforosi, Ramon Roozendaal, Richard M.W. Hoetelmans, Juan-José Pérez-Ruixo & Muriel Boulton. (2023) Mechanistic Model Describing the Time Course of Humoral Immunity Following Ad26.COV2.S Vaccination in Non-Human Primates. Journal of Pharmacology and Experimental Therapeutics 387:1, pages 121-130.
Crossref
Crossref
Anna Dari, Philippe Jacqmin, Yuki Iwaki, Martine Neyens, Mathieu Le Gars, Jerald Sadoff, Karin Hardt, Javier Ruiz‐Guiñazú & Juan José Pérez‐Ruixo. (2023) Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID‐19 vaccine Ad26.COV2.S in humans. CPT: Pharmacometrics & Systems Pharmacology 12:10, pages 1485-1498.
Crossref
Crossref
Andrew Lim, Pradeep Sharma, Oleg Stepanov & Venkatesh Pilla Reddy. (2023) Application of Modelling and Simulation Approaches to Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies in Pediatric Population. Pharmaceutics 15:5, pages 1552.
Crossref
Crossref
Mendy ter Avest, Saskia M. C. Langemeijer, Nicole M. A. Blijlevens, Nicole C. A. J. van de Kar & Rob ter Heine. (2022) Dose optimalization of subcutaneous ravulizumab is predicted to yield significant savings and to improve patient friendliness. British Journal of Clinical Pharmacology 89:3, pages 1211-1215.
Crossref
Crossref
David Fairman & Huaping Tang. (2023) Best Practices in mAb and Soluble Target Assay Selection for Quantitative Modelling and Qualitative Interpretation. The AAPS Journal 25:1.
Crossref
Crossref
Anna Dari, Muriel Boulton, Martine Neyens, Mathieu Le Gars, Belén Valenzuela, Georgi Shukarev, Vicky Cárdenas, Javier Ruiz‐Guiñazú, Jerald Sadoff, Richard M. W. Hoetelmans & Juan José Pérez Ruixo. (2022)
Quantifying Antibody Persistence After a Single Dose of
COVID
‐19 Vaccine Ad26.
COV2
.S in Humans Using a Mechanistic Modeling and Simulation Approach
. Clinical Pharmacology & Therapeutics 113:2, pages 380-389.
Crossref
Crossref
Phyllis Chan, Kirill Peskov & Xuyang Song. (2022) Applications of Model-Based Meta-Analysis in Drug Development. Pharmaceutical Research 39:8, pages 1761-1777.
Crossref
Crossref
Anders Soehoel, Malte Selch Larsen & Stine Timmermann. (2022) Population Pharmacokinetics of Tralokinumab in Adult Subjects With Moderate to Severe Atopic Dermatitis. Clinical Pharmacology in Drug Development 11:8, pages 910-921.
Crossref
Crossref
Bryan T. Mayer, Allan C. deCamp, Yunda Huang, Joshua T. Schiffer, Raphael Gottardo, Peter B. Gilbert & Daniel B. Reeves. (2022) Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention. PLOS Computational Biology 18:4, pages e1010003.
Crossref
Crossref
A. I. Platova. (2022) Population pharmacokinetics analysis in Lixoft Monolix softwares. Pharmacokinetics and Pharmacodynamics:3, pages 36-51.
Crossref
Crossref
Vittal Shivva, Martin Fink & Philip J. Lowe. (2021) Improving priors for human monoclonal antibody linear pharmacokinetic parameters by using half-lives from non-human primates. Journal of Pharmacokinetics and Pharmacodynamics 48:2, pages 295-303.
Crossref
Crossref
Yu Tang & Yanguang Cao. (2021) Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions. Pharmaceutics 13:3, pages 422.
Crossref
Crossref
Xiaoyu Yan, Juan Jose Perez Ruixo & Wojciech Krzyzanski. (2020) Dose Correction for a Michaelis–Menten Approximation of a Target-Mediated Drug Disposition Model with a Multiple Intravenous Dosing Regimens. The AAPS Journal 22:2.
Crossref
Crossref
Eugènia SantacanaLorena Rodríguez-AlonsoAriadna PadullésJordi GuardiolaJordi Bas, Francisco Rodríguez-MorantaKatja SerraFrancisco Morandeira, Helena ColomNúria Padullés. (2020) Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design. Therapeutic Drug Monitoring 42:1, pages 102-110.
Crossref
Crossref
Laura Bonifacio, Michael Dodds, David Prohaska, Aaron Moss, Amato Giaccia, Ray Tabibiazar & Gail McIntyre. (2019) Target‐Mediated Drug Disposition Pharmacokinetic/Pharmacodynamic Model‐Informed Dose Selection for the First‐in‐Human Study of AVB‐S6‐500. Clinical and Translational Science 13:1, pages 204-211.
Crossref
Crossref
Bruce A. Kerwin, Chelsey Bennett, Yan Brodsky, Rutilio Clark, J. Alaina Floyd, Alison Gillespie, Bryan T. Mayer, Megan McClure, Christine Siska, Michael S. Seaman, Kelly E. Seaton, Jeremy Shaver, Georgia D. Tomaras, Nicole L. Yates & Randal R. Ketchem. (2020) Framework Mutations of the 10-1074 bnAb Increase Conformational Stability, Manufacturability, and Stability While Preserving Full Neutralization Activity. Journal of Pharmaceutical Sciences 109:1, pages 233-246.
Crossref
Crossref
Colby S. Shemesh, Pascal Chanu, Kris Jamsen, Russ Wada, Gianluca Rossato, Francis Donaldson, Amit Garg, Helen Winter, Jane Ruppel, Xin Wang, Rene Bruno, Jin Jin & Sandhya Girish. (2019) Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Crossref
Daan P. Hurkmans, Edwin A. Basak, Tanja van Dijk, Darlene Mercieca, Marco W. J. Schreurs, Annemarie J. M. Wijkhuijs, Sander Bins, Esther Oomen-de Hoop, Reno Debets, Markus Joerger, Arlette Odink, Astrid A. M. van der Veldt, Cor H. van der Leest, Joachim G. J. V. Aerts, Ron H. J. Mathijssen & Stijn L. W. Koolen. (2019) A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Crossref
Yehuda Z. Cohen, Allison L. Butler, Katrina Millard, Maggi Witmer-Pack, Rebeka Levin, Cecilia Unson-O’Brien, Roshni Patel, Irina Shimeliovich, Julio C. C. Lorenzi, Jill Horowitz, Stephen R. Walsh, Shu Lin, Joshua A. Weiner, Anna Tse, Alicia Sato, Chelsey Bennett, Bryan Mayer, Kelly E. Seaton, Nicole L. Yates, Lindsey R. Baden, Allan C. deCamp, Margaret E. Ackerman, Michael S. Seaman, Georgia D. Tomaras, Michel C. Nussenzweig & Marina Caskey. (2019) Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. PLOS ONE 14:8, pages e0219142.
Crossref
Crossref
Kenneth W. Walker, Hossein Salimi-Moosavi, Gregory E. Arnold, Qing Chen, Marcus Soto, Frederick W. Jacobsen & John Hui. (2019) Pharmacokinetic comparison of a diverse panel of non-targeting human antibodies as matched IgG1 and IgG2 isotypes in rodents and non-human primates. PLOS ONE 14:5, pages e0217061.
Crossref
Crossref
Mohamad Shebley, Rajeev M. Menon, John P. Gibbs, Nimita Dave, Su Y. Kim & Patrick J. Marroum. (2018) Accelerating Drug Development in Pediatric Oncology With the Clinical Pharmacology Storehouse. The Journal of Clinical Pharmacology 59:5, pages 625-637.
Crossref
Crossref
Honghui Zhou & Diane R. MouldTimothy J. Taylor, Bill Frame & Angela D. Taylor. 2019. Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune‐Mediated Inflammatory Diseases. Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune‐Mediated Inflammatory Diseases
93
124
.
David Ternant, Nicolas Azzopardi, William Raoul, Theodora Bejan-Angoulvant & Gilles Paintaud. (2018) Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans. Clinical Pharmacokinetics 58:2, pages 169-187.
Crossref
Crossref
Rong Deng, C. Andrew Boswell, Wendy S. Putnam, Meina T. Tang, Amit Garg, Chunze Li, Shan Chung & Sandhya Girish. 2019. Pharmaceutical Biotechnology. Pharmaceutical Biotechnology
151
190
.
F. Morschhauser, B. Dekyndt, C. Baillet, C. Barthélémy, E. Malek, J. Fulcrand, P. Bigot, D. Huglo, B. Décaudin, N. Simon & P. Odou. (2018) A new pharmacokinetic model for 90Y-ibritumomab tiuxetan based on 3-dimensional dosimetry. Scientific Reports 8:1.
Crossref
Crossref
A. Brekkan, S. Jönsson, M. O. Karlsson & A. C. Hooker. (2018) Reduced and optimized trial designs for drugs described by a target mediated drug disposition model. Journal of Pharmacokinetics and Pharmacodynamics 45:4, pages 637-647.
Crossref
Crossref
Josiah T. Ryman & Bernd Meibohm. (2017) Pharmacokinetics of Monoclonal Antibodies. CPT: Pharmacometrics & Systems Pharmacology 6:9, pages 576-588.
Crossref
Crossref
Gerald R. Galluppi, Nicolas Wisniacki & Chris Stebbins. (2016) Population pharmacokinetic and pharmacodynamic analysis of BIIB023, an anti-TNF-like weak inducer of apoptosis (anti-TWEAK) monoclonal antibody. British Journal of Clinical Pharmacology 82:1, pages 118-128.
Crossref
Crossref
Steven KathmanJr.Jr., Theingi M. Thway, Lei Zhou, Stephanie Lee, Steven Yu, Mark Ma, Naren Chirmule & Vibha Jawa. (2016) Utility of a Bayesian Mathematical Model to Predict the Impact of Immunogenicity on Pharmacokinetics of Therapeutic Proteins. The AAPS Journal 18:2, pages 424-431.
Crossref
Crossref
Mary E. Spilker, Pratap Singh & Paolo Vicini. (2015) Mathematical modeling of receptor occupancy data: A valuable technology for biotherapeutic drug development. Cytometry Part B: Clinical Cytometry 90:2, pages 230-236.
Crossref
Crossref